Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture
Status: | Recruiting |
---|---|
Conditions: | Cancer, Orthopedic |
Therapuetic Areas: | Oncology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 8 - 20 |
Updated: | 1/27/2019 |
Start Date: | May 2015 |
End Date: | June 2019 |
Contact: | Lynda Vrooman, MD |
Email: | lynda_vrooman@dfci.harvard.edu |
Phone: | (617) 632-2659 |
This research study is evaluating bone mineral density in childhood cancer survivors who have
a history of bone fracture.
a history of bone fracture.
The purpose of this research study is to learn more about the status of bones in children and
young-adults who have had bone fractures after treatment for childhood cancer. Bone
complications including fracture can be important issues for some childhood cancer survivors.
In this study we are measuring bone mineral density in children and young adults who have had
bone fracture after treatment for childhood cancer. We will measure bone mineral density in
two ways. We will use: 1) dual energy x-ray absorptiometry (also known as DXA), and 2)
peripheral quantitative computed tomography (also known as pQCT).
young-adults who have had bone fractures after treatment for childhood cancer. Bone
complications including fracture can be important issues for some childhood cancer survivors.
In this study we are measuring bone mineral density in children and young adults who have had
bone fracture after treatment for childhood cancer. We will measure bone mineral density in
two ways. We will use: 1) dual energy x-ray absorptiometry (also known as DXA), and 2)
peripheral quantitative computed tomography (also known as pQCT).
Inclusion Criteria:
- History of childhood cancer
- Age ≥ 8 years and < 20 years at time of enrollment
- ≥ 2 years since completion of cancer-directed therapy for first cancer
- Received chemotherapy for treatment of childhood cancer
- History of bone fracture after the conclusion of chemotherapy*
- Not currently receiving cancer-directed therapy
- Signed written informed consent (by parent if patient is < 18 years of age, or by
patient, if he or she is ≥18 years of age)
- Patient assent for those ≥10 years of age and < 18 years of age for whom a parent
provides informed consent (*History of bone fracture will be based on patient/parent
report of fracture occurrence and will be confirmed in review of the medical record
whenever feasible.)
Exclusion Criteria:
- Current treatment with bisphosphonates (as of time of enrollment)
- Current treatment with the anticonvulsant depakote (at time of enrollment)
- Currently pregnant
We found this trial at
2
sites
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Lynda Vrooman, MD
Phone: 617-632-2659
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Lynda Vrooman, MD
Phone: 617-632-2659
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials